BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 32820684)

  • 41. [Clinical analysis of autologous hematopoietic stem cell transplantation in the treatment of advanced/recurrent nasal type extranodal NK/T-cell lymphoma].
    Yuan FF; Yin QS; Fu YW; Wang Q; Chen L; Mi RH; Li YF; Wei XD; Song YP
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):569-572. PubMed ID: 30122016
    [No Abstract]   [Full Text] [Related]  

  • 42. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.
    Wang L; Wang H; Wang JH; Xia ZJ; Lu Y; Huang HQ; Jiang WQ; Zhang YJ
    Oncotarget; 2015 Oct; 6(30):30317-26. PubMed ID: 26210287
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of chemotherapy with or without asparaginase for extranodal nasal NK/T-cell lymphoma in children and adolescents.
    Zhen Z; Huang H; Lin T; Li Z; Zhen X; Xia Z; Zhu J; Lu S; Sun F; Wang J; Huang J; Sun X
    Pediatr Blood Cancer; 2021 May; 68(5):e28901. PubMed ID: 33484107
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Extranodal natural killer/T cell lymphoma: we should and we can do more.
    Ying Z; Zhu J
    Chin Clin Oncol; 2015 Mar; 4(1):12. PubMed ID: 25841719
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Extranodal NK/T-cell lymphoma, nasal type: Clinical features, outcome, and prognostic factors in 101 cases.
    Su YJ; Wang PN; Chang H; Shih LY; Lin TL; Kuo MC; Chuang WY; Wu JH; Tang TC; Hung YS; Dunn P; Kao HW
    Eur J Haematol; 2018 Sep; 101(3):379-388. PubMed ID: 29908084
    [TBL] [Abstract][Full Text] [Related]  

  • 46. L-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type.
    Yong W; Zheng W; Zhu J; Zhang Y; Wang X; Xie Y; Lin N; Xu B; Lu A; Li J
    Ann Hematol; 2009 Jul; 88(7):647-52. PubMed ID: 19107482
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Extended Course and Increased Dose of Initial Chemotherapy for Extranodal Nasal Type Natural Killer/T (NK/T)-Cell Lymphoma in Patients <60 Years Old: A Single-Center Retrospective Cohort Study.
    Xu Y; Wang J; Zhang W; Liu J; Cao X; He A; Chen Y; Gu L; Lei B; Zhang P; Ma X
    Med Sci Monit; 2016 Nov; 22():4297-4311. PubMed ID: 27843135
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical features, prognostic stratification, and treatment of advanced-stage non-nasal type extranodal natural killer/T-cell lymphoma: a multi-institutional real-world study.
    Wei YC; Liu WX; Qi F; Zhang CG; Zheng BM; Xie Y; Chen B; Zhang D; Liu WP; Fang H; Chai Y; Qi SN; Li YX; Wang WH; Song YQ; Zhu J; Dong M
    Ann Hematol; 2024 Jan; 103(1):163-174. PubMed ID: 37817010
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.
    Yamaguchi M; Kwong YL; Kim WS; Maeda Y; Hashimoto C; Suh C; Izutsu K; Ishida F; Isobe Y; Sueoka E; Suzumiya J; Kodama T; Kimura H; Hyo R; Nakamura S; Oshimi K; Suzuki R
    J Clin Oncol; 2011 Nov; 29(33):4410-6. PubMed ID: 21990393
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Outcomes and prognostic factors of patients with Extranodal NK T cell lymphoma (ENKTL).
    Rajendra A; Sengar M; Bonda VNA; Jain H; Nayak L; Thorat J; Shet T; Epari S; Laskar S; Aggarwal A; Rangarajan V; Gujral S; Bagal B; Kakoti S; Salvi O
    Leuk Lymphoma; 2023 Dec; 64(12):1914-1926. PubMed ID: 37602660
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/T-Cell lymphoma, nasal type: A French study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
    Philippe Walter L; Couronné L; Jais JP; Nguyen PD; Blaise D; Pigneux A; Socié G; Thieblemont C; Bachy E; Fegueux N; Chevallier P; Mohty M; Yakoub-Agha I; Peffault de Latour R; Jaccard A; Hermine O;
    Am J Hematol; 2021 Jul; 96(7):834-845. PubMed ID: 33864708
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pralatrexate as a bridge to allogeneic hematopoietic stem cell transplantation in a patient with advanced-stage extranodal nasal-type natural killer/T cell lymphoma refractory to first-line chemotherapy: a case report.
    Liu YC; Lin TA; Wang HY; Ko PS; Liu CJ; Hsiao LT; Chien SH; Gau JP
    J Med Case Rep; 2020 Mar; 14(1):43. PubMed ID: 32183896
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Promising clinical outcomes of sequential and "Sandwich" chemotherapy and extended involved-field intensity-modulated radiotherapy in patients with stage I
    Wang HY; Niu SQ; Yang YY; Li YY; Chen HB; Zhang YJ
    Cancer Med; 2018 Dec; 7(12):5863-5869. PubMed ID: 30484966
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combined immune checkpoint blockade and radiotherapy induces durable remission in relapsed natural killer/T-cell lymphoma: a case report and review of the literature.
    McGehee E; Patel H; Pearson C; Clements K; Jaso JM; Chen W; Callan A; Desai N; Ramakrishnan Geethakumari P
    J Med Case Rep; 2021 Apr; 15(1):221. PubMed ID: 33926575
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Consolidative treatment after salvage chemotherapy improves prognosis in patients with relapsed extranodal natural killer/T-cell lymphoma.
    Nie M; Bi XW; Zhang WW; Sun P; Xia Y; Liu PP; Huang HQ; Jiang WQ; Li ZM
    Sci Rep; 2016 Apr; 6():23996. PubMed ID: 27041507
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Midtreatment ¹⁸F-FDG PET/CT Scan for Early Response Assessment of SMILE Therapy in Natural Killer/T-Cell Lymphoma: A Prospective Study from a Single Center.
    Khong PL; Huang B; Lee EY; Chan WK; Kwong YL
    J Nucl Med; 2014 Jun; 55(6):911-6. PubMed ID: 24819420
    [TBL] [Abstract][Full Text] [Related]  

  • 57. NK/T Cell Lymphoma: Updates in Therapy.
    Suzuki R
    Curr Hematol Malig Rep; 2018 Feb; 13(1):7-12. PubMed ID: 29368155
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.
    Jaccard A; Gachard N; Marin B; Rogez S; Audrain M; Suarez F; Tilly H; Morschhauser F; Thieblemont C; Ysebaert L; Devidas A; Petit B; de Leval L; Gaulard P; Feuillard J; Bordessoule D; Hermine O;
    Blood; 2011 Feb; 117(6):1834-9. PubMed ID: 21123825
    [TBL] [Abstract][Full Text] [Related]  

  • 59. L-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia.
    Jung KS; Cho SH; Kim SJ; Ko YH; Kang ES; Kim WS
    J Hematol Oncol; 2016 Apr; 9():41. PubMed ID: 27091029
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Efficacy of GLIDE chemotherapy for patients with newly diagnosed advanced-stage or relapsed/refractory extranodal natural killer cell lymphoma].
    Ji J; Xiang B; Liu ZG; Jia YQ; Zhu HL; Niu T; Pan L; Chang H; Huang J; Wu Y; Li JJ; He C; Ma HB; Tang Y; Dong T; Liu T
    Zhonghua Xue Ye Xue Za Zhi; 2016 Sep; 37(9):751-755. PubMed ID: 27719716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.